Emtricitabine, rilpivirine, and tenofovir alafenamide
- Part D specialty tier in 80% of formularies (2026Q3)
- ODEFSEY
Therapy management checklist
Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.
Loading the therapy management checklist…
Storage and cold chain
Emtricitabine, rilpivirine, and tenofovir alafenamide: storage and handling
- Freezing
- Not addressed
- Room temperature
- No allowance stated
- Back into the refrigerator
- Not addressed
- Light
- Not addressed
- Shaking
- Not addressed
All storage statements on the label (2)
- Store below 30°C (86°F).
- Store ODEFSEY below 86°F (30°C).
FDA label version 13, effective December 2, 2025. DailyMed
Dosing and titration calendar
Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.
Loading dosing schedules…
Medicare Part D coverage
5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan
Patient assistance
Product website printed on the label (www.odefsey.com)
Checked 2026-11-06.
Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.
For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.